Đang chuẩn bị nút TẢI XUỐNG, xin hãy chờ
Tải xuống
Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học General Psychiatry cung cấp cho các bạn kiến thức về ngành y đề tài: Cyclophosphamide in systemic sclerosis: still in search of a ‘real life’ scenario. | Available online http arthritis-research.eom content 11 1 103 Editorial Cyclophosphamide in systemic sclerosis still in search of a real life scenario Irene Miniati1 Gabriele Valentini2 and Marco Matucci Cerinic1 1 Department of Biomedicine Division of Rheumatology AOUC Denothe Center University of Florence Viale Pieraccini 18 50139 Florence Italy 2Department of Internal Medicine Rheumatology Unit Second University of Naples Via Pacifici 5 80131 Napoli Italy Corresponding author Marco Matucci Cerinic cerinic@unifi.it Published 23 January 2009 This article is online at http arthritis-research.com content 11 1 103 2009 BioMed Central Ltd Arthritis Research Therapy 2009 11 103 doi 10.1186 ar2576 See related research by Nannini et al. http arthritis-research.com content 10 5 R124 Abstract In systemic sclerosis SSc there is no proven treatment to prevent disease progression. In a recent meta-analysis of three randomised controlled trials RCTs and six open prospective studies on cyclophosphamide CYC no significant changes in lung function were observed. However CYC is associated with an improvement of Mahler s dyspnea index short form-36 physical and mental domains and health-related quality of life contributing to the amelioration of patients functional status. Further RCTs on early SSc are needed to assess the real efficacy of CYC in inducing remission and increasing survival. In a previous issue of Arthritis Research Therapy Nannini and colleagues 1 addressed the topic by a well-conducted meta-analysis and concluded that cyclophosphamide CYC treatment does not induce a statistically significant improvement in lung function in systemic sclerosis SSc interstitial lung disease ILD . This meta-analysis pooled the data from three randomised controlled trials RCTs and six observational studies and focused on the changes in pulmonary functional parameters forced vital capacity FVC and diffusing lung capacity for carbon monoxide DLCO of SSc patients treated with CYC for at .
